title: 2012 update in the treatment of prolactinomas.
abstract: New information has been provided over the last years regarding treatment of prolactinomas and will be reviewed in this update. Medical treatment with a dopamine agonist (DA) remains the cornerstone of therapy and cabergoline is the first choice, due to its high efficacy and good tolerability profile. Prolonged remission after discontinuation of DA may be observed if treatment has been given for at least two years, normal prolactin has been obtained with a low dose and tumoral diameter has been reduced by at least 50%. Although the risk of restrictive cardiac valve disease is low at the standard doses of cabergoline used for the treatment of hyperprolactinaemia, long-term echocardiographic surveillance is however indicated, in particular in resistant patients who need higher doses of cabergoline (2.0 mg/week or more). Neurosurgical treatment of prolactinomas is less effective than medical therapy and recurrence of hyperprolactinaemia is frequent. Besides classical indications such as drug intolerance, resistance or acute complications, new indications have emerged such as young patients with a high likelihood of complete tumour resection and who do not wish to take prolonged medical treatment, or patients who require high doses of cabergoline, in whom surgical debulking may significantly improve postoperative hormonal control. Finally, recent data indicate that cabergoline is safe for the developing foetus and for the mother, and therefore should not be preventively withdrawn in a young woman wishing to become pregnant.
authors.affiliation: Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. dominique.maiter@uclouvain.be
authors.forename: Dominique
authors.initials: D
authors.lastname: Maiter
authors.forename: Vanessa
authors.initials: V
authors.lastname: Primeau
mesh_terms: D000077465:Cabergoline; D000075202:Contraindications; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use; D004704:Endocrinology / Q000379:methods / Q000639:trends*; D004873:Ergolines / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D019635:Neurosurgical Procedures / Q000379:methods / Q000706:statistics & numerical data; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline